International Journal of Molecular Sciences Article Genomic, Clinical, and Behavioral Characterization of 15q11.2 BP1-BP2 Deletion (Burnside-Butler) Syndrome in Five Families Isaac Baldwin 1,2,† , Robin L. Shafer 3,† , Waheeda A. Hossain 1,2, Sumedha Gunewardena 4, Olivia J. Veatch 1,4, Matthew W. Mosconi 3,5 and Merlin G. Butler 1,2,* 1 Department of Psychiatry & Behavioral Sciences, University of Kansas Medical Center, 3901 Rainbow Blvd. MS 4015, Kansas City, KS 66160, USA;
[email protected] (I.B.);
[email protected] (W.A.H.);
[email protected] (O.J.V.) 2 Department of Pediatrics, University of Kansas Medical Center, 3901 Rainbow Blvd. MS 4015, Kansas City, KS 66160, USA 3 Schiefelbusch Institute for Life Span Studies and Kansas Center for Autism Research and Training, University of Kansas, Lawrence, KS 66045, USA;
[email protected] (R.L.S.);
[email protected] (M.W.M.) 4 Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS 66160, USA;
[email protected] 5 Clinical Child Psychology Program, University of Kansas, Lawrence, KS 66045, USA * Correspondence:
[email protected] † Represents co-first authorship. Abstract: The 15q11.2 BP1-BP2 deletion (Burnside-Butler) syndrome is emerging as the most com- mon cytogenetic finding in patients with neurodevelopmental or autism spectrum disorders (ASD) presenting for microarray genetic testing. Clinical findings in Burnside-Butler syndrome include developmental and motor delays, congenital abnormalities, learning and behavioral problems, and Citation: Baldwin, I.; Shafer, R.L.; abnormal brain findings. To better define symptom presentation, we performed comprehensive cog- Hossain, W.A.; Gunewardena, S.; Veatch, O.J.; Mosconi, M.W.; Butler, nitive and behavioral testing, collected medical and family histories, and conducted clinical genetic M.G.